ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma

被引：13
|
作者：
Foerster, Friedrich
Kloeckner, Roman
Reig, Maria
Chan, Stephen Lam
Chung, Jin Wook
Merle, Philippe
Park, Joong-Won
Piscaglia, Fabio
Vogel, Arndt
Gaillard, Vincent
Bruix, Jordi
Galle, Peter R.
机构：
[1] Johannes Gutenberg Univ Mainz, Dept Internal Med 1, Univ Med Ctr, Mainz, Germany
[2] Johannes Gutenberg Univ Mainz, Dept Diagnost & Intervent Radiol, Univ Med Ctr, Mainz, Germany
[3] Hosp Clin Barcelona, BCLC Grp, Liver Unit, CIBEREHD, Barcelona, Spain
[4] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[5] Seoul Natl Univ Hosp, Seoul, South Korea
[6] Croix Rousse Hosp, Hepatol Unit, Lyon, France
[7] Natl Canc Ctr, Goyang, South Korea
[8] IRCCS Azienda Osped Univ Bologna, Bologna, Italy
[9] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[10] F Hoffmann La Roche Ltd, Basel, Switzerland
[11] Univ Barcelona, CIBEREHD, BCLC Grp, Liver Unit,Hosp Clin,IDIBAPS, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS498
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS498
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate-stage Hepatocellular Carcinoma: A Multicenter Retrospective Study
    Zheng, Yitao
    Xiang, Yanjun
    Shi, Hongqi
    Lin, Zhuoqun
    Cheng, Shuqun
    Zhu, Jiuting
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1079 - 1093
  • [2] Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial.
    Kudo, Masatoshi
    Ueshima, Kazuomi
    Ikeda, Masafumi
    Torimura, Takuji
    Tanabe, Nobukazu
    Aikata, Hiroshi
    Izumi, Namiki
    Yamasaki, Takahiro
    Nojiri, Shunsuke
    Hino, Keisuke
    Tsumura, Hidetaka
    Kuzuya, Teiji
    Isoda, Norio
    Yasui, Kohichiroh
    Yoshimura, Kenichi
    Okusaka, Takuji
    Furuse, Junji
    Kokudo, Norihiro
    Okita, Kiwamu
    Arai, Yasuaki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [3] LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC)
    El-Khoueiry, Anthony B.
    Llovet, Josep M.
    Vogel, Arndt
    Madoff, David C.
    Finn, Richard S.
    Ogasawara, Sadahisa
    Ren, Zhenggang
    Mody, Kalgi
    Li, Jerry J.
    Siegel, Abby B.
    Dubrovsky, Leonid
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [4] Therapeutic approaches in intermediate-stage hepatocellular carcinoma (HCC): a novel insight of adjuvant transarterial chemoembolization (TACE)
    Fernandez-Palanca, Paula
    Mauriz, Jose L.
    CHINESE CLINICAL ONCOLOGY, 2023, 12 (02)
  • [5] Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review
    Ai, Haidong
    Gong, Ting
    Ma, Yongbiao
    Ma, Guixu
    Ding, Wei
    Ding, Weibao
    Wang, Wenjuan
    Zhao, Xuelin
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [6] TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization combined with atezolizumab plus bevacizumab or on-demand transarterial chemoembolization alone in patients with untreated hepatocellular carcinoma
    Kudo, Masatoshi
    Guo, Yabing
    Hua, Yongqiang
    Zhao, Ming
    Xing, Wenge
    Zhang, Yonghong
    Liu, Ruibao
    Ren, Zhenggang
    Gu, Shanzhi
    Lin, Zhengyu
    Lv, Weifu
    Wang, Yumeng
    Dong, Jiahong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [7] Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2022, 11 (05) : 399 - 406
  • [8] Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: The DEMAND randomized phase II clinical trial
    De Toni, Enrico N.
    Kubisch, Ilja
    Ben Khaled, Najib
    Ricke, Jens
    Mayerle, Julia
    Ehmer, Ursula
    Waldschmidt, Dirk
    Roessler, Daniel Christoph
    Oehrle, Bettina
    Bitzer, Michael
    Kandulski, Arne
    Reuken, Philipp A.
    Wege, Henning
    Seidensticker, Max
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
    Llovet, J. M.
    El-Khoueiry, A. B.
    Vogel, A.
    Madoff, D. C.
    Finn, R. S.
    Ogasawara, S.
    Ren, Z.
    Mody, K.
    Li, J. Jing
    Siegel, A. B.
    Dubrovsky, L.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S702 - S703
  • [10] Transarterial chemoembolization (TACE) with or without lenvatinib (len) plus pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study
    Llovet, J.
    Finn, R. S.
    Ren, Z.
    Guo, Y.
    Han, G.
    Lin, H.
    Zheng, J.
    Ogasawara, S.
    Li, H.
    Kim, J. H.
    Zhao, H.
    Li, C.
    Madoff, D. C.
    Ghobrial, R. M.
    El-Khoueiry, A. B.
    Vogel, A.
    Peng, X.
    Mody, K.
    Dubrovsky, L.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2024, 35 : 1229 - 1229
12345